CDTX Stock Overview
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Cidara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.00 |
| 52 Week High | US$29.60 |
| 52 Week Low | US$10.00 |
| Beta | 1.01 |
| 1 Month Change | -12.16% |
| 3 Month Change | -2.24% |
| 1 Year Change | -37.50% |
| 3 Year Change | -71.62% |
| 5 Year Change | -71.11% |
| Change since IPO | -95.94% |
Recent News & Updates
Recent updates
We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth
Sep 28
Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop
Apr 17Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year
Mar 25We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely
Mar 14Cidara spikes on $11M milestone payment from partner Mundipharma
Oct 04Cidara begins dosing of antiviral CD388 in trial for preventing influenza
Sep 13Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M
Aug 09Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts
Dec 17Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic
Aug 17Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?
Aug 04Cidara Therapeutics: Rezafungin Data Could Bring Value
Jul 20We Think Some Shareholders May Hesitate To Increase Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) CEO Compensation
Jun 17Shareholder Returns
| CDTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.0% | 0.4% | 1.0% |
| 1Y | -37.5% | 0.9% | 21.9% |
Return vs Industry: CDTX underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: CDTX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| CDTX volatility | |
|---|---|
| CDTX Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CDTX's share price has been volatile over the past 3 months.
Volatility Over Time: CDTX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 69 | Jeff Stein | www.cidara.com |
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.
Cidara Therapeutics, Inc. Fundamentals Summary
| CDTX fundamental statistics | |
|---|---|
| Market cap | US$59.30m |
| Earnings (TTM) | -US$22.93m |
| Revenue (TTM) | US$63.91m |
0.9x
P/S Ratio-2.6x
P/E RatioIs CDTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDTX income statement (TTM) | |
|---|---|
| Revenue | US$63.91m |
| Cost of Revenue | US$70.06m |
| Gross Profit | -US$6.15m |
| Other Expenses | US$16.78m |
| Earnings | -US$22.93m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.03 |
| Gross Margin | -9.62% |
| Net Profit Margin | -35.88% |
| Debt/Equity Ratio | 0% |
How did CDTX perform over the long term?
See historical performance and comparison